Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012;(1):CD003261.
1. Hartman-Adams H, Banvard C, Juckett G. Impetigo: diagnosis and treatment. Am Fam Physician. 2014;90:229-235.
2. Elliot AJ, Cross KW, Smith GE, et al. The association between impetigo, insect bites and air temperature: a retrospective 5-year study (1999-2003) using morbidity data collected from a sentinel general practice network database. Fam Pract. 2006;23:490-496.
3. Kakar N, Kumar V, Mehta G, et al. Clinico-bacteriological study of pyodermas in children. J Dermatol. 1999;26:288-293.
4. Tewodros W, Muhe L, Daniel E, et al. A one-year study of streptococcal infections and their complications among Ethiopian children. Epidemiol Infect. 1992;109:211-225.
5. Loffeld A, Davies P, Lewis A, et al. Seasonal occurrence of impetigo: a retrospective 8-year review (1996-2003). Clin Exp Dermatol. 2005;30:512-514.
6. Kristensen JK. Scabies and pyoderma in Lilongwe, Malawi. Prevalence and seasonal fluctuation. Int J Dermatol. 1991;30:699-702.
7. Durupt F, Mayor L, Bes M, et al. Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br J Dermatol. 2007;157:1161-1167.
8. Shi D, Higuchi W, Takano T, et al. Bullous impetigo in children infected with methicillin-resistant Staphylococcus aureus alone or in combination with methicillin-susceptible S. aureus: analysis of genetic characteristics, including assessment of exfoliative toxin gene carriage. J Clin Microbiol. 2011;49:1972-1974.
9. Hay R, Adriaans B. Bacterial Infections. In: Burns T, Breathnach S, Cox N, et al., eds. Rook's Textbook of Dermatology. 7th ed. Malden, MA: Blackwell Science; 2004:1221-1306.
10. Amagai M, Matsuyoshi N, Wang ZH, et al. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat Med. 2000;6:1275-1277.
11. Hanakawa Y, Schechter NM, Lin C, et al. Molecular mechanisms of blister formation in bullous impetigo and staphylococcal scalded skin syndrome. J Clin Invest. 2002;110:53-60.
12. Weedon D. Weedon's skin pathology. Third ed. Churchill Livingstone, Elsevier; 2009:549.
13. Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev. 2011;(7):CD006207.
14. Luby SP, Agboatwalla M, Feikin DR, et al. Effect of handwashing on child health: a randomised controlled trial. Lancet. 2005;366:225-233.
15. Scully BE, Briones F, Gu JW, et al. Mupirocin treatment of nasal staphylococcal colonization. Arch Intern Med. 1992;152:353-356.
16. Raz R, Miron D, Colodner R, et al. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med. 1996;156:1109-1112.
17. Darmstadt GL, Osendarp SJ, Ahmed S, et al. Effect of antenatal zinc supplementation on impetigo in infants in Bangladesh. Pediatr Infect Dis J. 2012;31:407-409.
18. Turnidge J, Collignon P. Resistance to fusidic acid. Int J Antimicrob Agents. 1999;12:S35-S44.
19. Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother. 1992;36:287-290.
20. Koning S, van der Sande R, Verhagen AP, et al. Interventions for impetigo. Cochrane Database Syst Rev. 2012;(1):CD003261.
21. Wallin TR, Hern HG, Frazee BW. Community-associated methicillin-resistant Staphylococcus aureus. Emerg Med Clin North Am. 2008; 26:431-455.
22. Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. Br J Dermatol 2008;158:1077-1082.
23. Barton LL, Friedman AD. Impetigo: a reassessment of etiology and therapy. Pediatr Dermatol. 1987;4:185-188.
24. Noguchi N, Nishijima S, Kurokawa I, et al. Antimicrobial agent of susceptibilities and antiseptic resistance gene distribution among methicillin-resistant Staphylococcus aureus isolates from patients with impetigo and staphylococcal scalded skin syndrome. J Clin Microbiol. 2006;44:2119-2125.
25. Bowen AC, Tong SY, Andrews RM, et al. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. Lancet. 2014;384:2132-2140.
26. McLinn S. A bacteriologically controlled, randomized study comparing the efficacy of 2% mupirocin ointment (Bactroban) with oral erythromycin in the treatment of patients with impetigo. J Am Acad Dermatol. 1990;22:883-885.
27. US National Institutes of Health; ClinicalTrials.gov. Efficacy and safety of ozenoxacin 1% cream versus placebo in the treatment of patients with impetigo. https://clinicaltrials.gov/ (last accessed 28 October 2016).
使用此内容应接受我们的免责声明。
BMJ临床实践的持续改进离不开您的帮助和反馈。如果您发现任何功能问题和内容错误,或您对BMJ临床实践有任何疑问或建议,请您扫描右侧二维码并根据页面指导填写您的反馈和联系信息*。一旦您的建议在我们核实后被采纳,您将会收到一份小礼品。
如果您有紧急问题需要我们帮助,请您联系我们。
邮箱:bmjchina.support@bmj.com
电话:+86 10 64100686-612
*您的联系信息仅会用于我们与您确认反馈信息和礼品事宜。
BMJ临床实践官方反馈平台